Medicare’s $50 Wegovy Copay Starts July 1, But Eligibility Is Very Narrow

TL;DR Summary
Starting July 1, 2026, Medicare will offer Wegovy and other GLP-1 weight‑loss drugs for a $50 monthly copay through a temporary GLP‑1 Bridge outside Part D that runs through December 31, 2027. Eligibility is tightly restricted by BMI and comorbidities and requires Part D enrollment; those with type 2 diabetes, sleep apnea, or certain liver diseases are excluded and must pursue Part D coverage instead. The $50 copay is outside Part D and does not count toward deductibles or the $2,100 out‑of‑pocket limit. Beneficiaries should verify their plan, gather medical documentation, and work with a clinician to determine if they meet the three eligible tiers.
- As of July 1, Medicare Covers Wegovy for Weight Loss at $50 a Month. The Eligibility List Is Short. 24/7 Wall St.
- One in eight U.S. adults uses GLP-1 drugs; Medicare now opens weight-loss access KOMO
- How a New Medicare Program Could Drive Up GLP-1 Use U.S. News - Money
- Medicare Pays Billions For Obesity’s Consequences. Its GLP-1 Bridge Offers A Better Way Pacific Research Institute (PRI)
- The Hidden Catch Behind $50 GLP-1s on Medicare Kiplinger
Reading Insights
Total Reads
0
Unique Readers
28
Time Saved
20 min
vs 21 min read
Condensed
97%
4,050 → 105 words
Want the full story? Read the original article
Read on 24/7 Wall St.